培美曲塞治疗晚期非小细胞肺癌的临床观察  

Clinical observation of pemetrexed for treating advanced NSCLC

作　　者：许杨[1] 汪济东[1] 

机构地区：[1]中国人民解放军海军安庆医院肿瘤内科,安徽安庆246003

出　　处：《现代医药卫生》2010年第24期3707-3709,共3页Journal of Modern Medicine & Health

摘　　要：目的:探讨培美曲塞治疗晚期转移性非小细胞肺癌(NSCLC)的疗效和不良反应。方法:经病理学确诊的晚期转移性肺癌4例,1例初治,3例为复治患者,评分0～3分,采用单药培美曲塞或联合顺铂或联合卡铂方案,即第一天培美曲塞500mg/㎡静脉注射/常规剂量应用联合顺铂或卡铂,每3周为1个周期重复,每2个周期评估疗效及不良反应。结果:4例均可评价疗效者,1例CR,2例PR,1例PD。因3例尚存活,不作生存期(率)评价。主要不良反应为中性粒细胞减少、胃肠道反应和末梢神经感觉障碍,其中1例有明显相关的疲乏感。结论:培美曲塞治疗晚期转移性非小细胞肺癌疗效良好,不良反应可接受。Objective：To evaluate the clinical effect and toxicity of pemetrexed in treating advanced non-smal-cell lung cancer（NSCLC）.Methods：4 patients with metastatic advanced NSCLC diagnosed by pathology were enrolled in the study,1 case was first treated and 3 cases were retreated.The patients received the chemotherapeutic regimens of simple pemetrexed or combined cisplatin or combined carboplatin.Every 3 weeks formed 1 cycle.The curative effects and adverse reactions were evaluated after 2 cycles.Results：Complete remission（CR） was observed in 1 case,partial remission（PR） in 2 cases and PD in 1 case.The main adverse reactions were leucope-nia,gastrointestinal reaction and sensory disturbance of peripheral nerve.Conclusion：Pemetrexed is effective,safe and well-tolerable in the treatment of metastatic advanced NSCLC.

关 键 词：培美曲塞 晚期非小细胞肺癌 化疗 

分 类 号：R73[医药卫生—肿瘤]